



ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liggett, Stephen B.

Application No.: 09/856,803

Group No.: 1648

Filed: 05/25/2001

Examiner: To be Assigned

For: Polymorphisms in the 5' Leader Cistron of the Beta2-Adrenergic Receptor

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

RECEIVED

JUN 2 1 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

- 1. Attached is a copy of the official corrected filing receipt received from the PTO in the above application for which issuance of a second corrected filing receipt is respectfully requested.
- 2. There are errors with respect to the following, which are incorrectly entered.

Error in

Correct data

1. Title:

1. Polymorphisms in the 5' Leader Cistron of the Beta2-Adrenergic Receptor

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. section 1.8a)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C.

20231.

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Signature

4.5.02 Date:

(type or print name of person certifying)

(Request for Corrected Filing Receipt--page 1 of 2)

- 3. The corrections are not due to any error by applicant and no fee is due.
- 4. The corrections are noted in red on the attached copy of the filing receipt.

Date: 4/5/02

Reg. No.: 47,562 Tel. No.: 203-786-3473

gnature of Practitioner

Gisela M. Field

Genaissance Pharmaceuticals, Inc.

Five Science Park

New Haven, CT 06511



United States Patent and Trademark Office



UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.usdio.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/856,803	05/25/2001	1648	1162	MWH- 0029US	8	26	8

25106 GENAISSANCE PHARMACEUTICALS 5 SCIENCE PARK

NEW HAVEN, CT 06511



CONFIRMATION NO. 3706
CORRECTED FILING RECEIPT
OC000000007627306

Date Mailed: 03/13/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stephen B. Liggett, Cincinnati, OH;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/L/7963 11/24/1999 WHICH CLAIMS BENEFIT OF 60/109,886 11/25/1998

Foreign Applications

If Required, Foreign Filing License Granted 03/12/2002

Projected Publication Date: Not Applicable, filed prior to Application Date: Not Applicable, filed prior to Application Date: Not Applicable, filed prior to Application Date: Not Applicable, filed prior to Appl

Non-Publication Request: No

Early Publication Request: No

Title

Polymorphisms in the 5' leader cistron of the beta2-adrenergie/receptor

Preliminary Class

435

adrenergic

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).